The 2016 International Liver Cancer Association Annual Conference took place in Vancouver, Canada from September 9 to 11, 2016.
The 10th ILCA Annual Conference welcomed over 600 participants from 46 different countries and proved to be a great success!
This multidisciplinary meeting is an outstanding scientific forum for all clinical, translational and basic researchers, physicians and allied professionals across liver cancer related disciplines to exchange their experiences and best practices.
The 10th ILCA Annual Conference welcomed over 600 participants from 46 different countries and proved to be a great success!
This multidisciplinary meeting is an outstanding scientific forum for all clinical, translational and basic researchers, physicians and allied professionals across liver cancer related disciplines to exchange their experiences and best practices.
Conference articles and multimedia coverage is available online at OncLive.
Conference Articles
Conflicting Evidence Surfaces on Anti-HCV Drugs for Liver Cancer
A new generation of drugs has proved highly effective against the hepatitis C virus but there is conflicting evidence about whether the therapies promote cancer recurrence in infected patients with hepatocellular carcinoma who already have responded to curative treatment.
Expert Describes Potential Therapeutic Vaccine for Advanced HCC
Ghassan K. Abou-Alfa, MD, discusses research into the use of the immunotherapeutic vaccinia virus Pexa-Vec as a frontline treatment for advanced hepatocellular carcinoma.
New Roles May Evolve for Competing Embolization Techniques in HCC
Two competing methods of delivering locoregional therapy to patients with hepatocellular carcinoma both have advantages and may be most successful in subgroups of individuals with intermediate-stage disease.
Large Analysis Sheds Light on Risk Factors for Non-Cirrhotic NASH-Associated HCC
About one quarter of patients with nonalcoholic steatohepatitis-associated hepatocellular carcinoma present without cirrhosis at diagnosis, suggesting a crucial subset of patients for future research with implications for HCC screening and surveillance.
Nivolumab Maintains Positive Results in Latest HCC Findings
Nivolumab continues to post durable responses in patients with advanced hepatocellular carcinoma regardless of whether they had hepatitis B or C or whether they had received prior treatment with sorafenib.
Regorafenib Moves Ahead of Field With Success in Advanced HCC
After 9 years of failed trials for once-promising drugs, regorafenib (Stivarga) has emerged as the clear choice for second-line therapy in advanced hepatocellular carcinoma after demonstrating survival improvements for patients whose disease has progressed after systemic treatment.
Regorafenib Poised as Second-Line Standard of Care in HCC
Although regorafenib is not currently approved, Morris Sherman, MD, PhD, already views the agent as the standard second-line therapy, with hopes for moving the agent into the frontline setting.
Early Signals Positive for Immunotherapy Plus Standard Therapy in HCC
Early evidence suggests that the combination of locoregional therapy with an immune checkpoint inhibitor is a safe and effective strategy to pursue for patients with advanced hepatocellular carcinoma.
Liver Cancer Experts Mark a Decade of Milestones in HCC
Although it has been nearly 10 years since a new drug was approved for the treatment of patients with hepatocellular carcinoma, the past decade has been marked by advances on the scientific and radiology fronts and the prospects for the development of new therapies are bright.
A new generation of drugs has proved highly effective against the hepatitis C virus but there is conflicting evidence about whether the therapies promote cancer recurrence in infected patients with hepatocellular carcinoma who already have responded to curative treatment.
Expert Describes Potential Therapeutic Vaccine for Advanced HCC
Ghassan K. Abou-Alfa, MD, discusses research into the use of the immunotherapeutic vaccinia virus Pexa-Vec as a frontline treatment for advanced hepatocellular carcinoma.
New Roles May Evolve for Competing Embolization Techniques in HCC
Two competing methods of delivering locoregional therapy to patients with hepatocellular carcinoma both have advantages and may be most successful in subgroups of individuals with intermediate-stage disease.
Large Analysis Sheds Light on Risk Factors for Non-Cirrhotic NASH-Associated HCC
About one quarter of patients with nonalcoholic steatohepatitis-associated hepatocellular carcinoma present without cirrhosis at diagnosis, suggesting a crucial subset of patients for future research with implications for HCC screening and surveillance.
Nivolumab Maintains Positive Results in Latest HCC Findings
Nivolumab continues to post durable responses in patients with advanced hepatocellular carcinoma regardless of whether they had hepatitis B or C or whether they had received prior treatment with sorafenib.
Regorafenib Moves Ahead of Field With Success in Advanced HCC
After 9 years of failed trials for once-promising drugs, regorafenib (Stivarga) has emerged as the clear choice for second-line therapy in advanced hepatocellular carcinoma after demonstrating survival improvements for patients whose disease has progressed after systemic treatment.
Regorafenib Poised as Second-Line Standard of Care in HCC
Although regorafenib is not currently approved, Morris Sherman, MD, PhD, already views the agent as the standard second-line therapy, with hopes for moving the agent into the frontline setting.
Early Signals Positive for Immunotherapy Plus Standard Therapy in HCC
Early evidence suggests that the combination of locoregional therapy with an immune checkpoint inhibitor is a safe and effective strategy to pursue for patients with advanced hepatocellular carcinoma.
Liver Cancer Experts Mark a Decade of Milestones in HCC
Although it has been nearly 10 years since a new drug was approved for the treatment of patients with hepatocellular carcinoma, the past decade has been marked by advances on the scientific and radiology fronts and the prospects for the development of new therapies are bright.
View all updates, here....
No comments:
Post a Comment